nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—ADA—pleura—sarcoma	0.153	0.308	CbGeAlD
Vidarabine—ADK—mammary gland—sarcoma	0.0186	0.0375	CbGeAlD
Vidarabine—Adenosine monophosphate—CREB1—sarcoma	0.0169	0.712	CrCbGaD
Vidarabine—ADA—myometrium—sarcoma	0.0161	0.0325	CbGeAlD
Vidarabine—ADA—hematopoietic system—sarcoma	0.0139	0.0279	CbGeAlD
Vidarabine—ADA—connective tissue—sarcoma	0.0133	0.0269	CbGeAlD
Vidarabine—ADK—myometrium—sarcoma	0.0132	0.0266	CbGeAlD
Vidarabine—ADORA2A—hematopoietic system—sarcoma	0.0126	0.0254	CbGeAlD
Vidarabine—DPP4—embryo—sarcoma	0.0123	0.0248	CbGeAlD
Vidarabine—ADK—seminal vesicle—sarcoma	0.0119	0.024	CbGeAlD
Vidarabine—DPP4—seminal vesicle—sarcoma	0.0115	0.0233	CbGeAlD
Vidarabine—ADK—hematopoietic system—sarcoma	0.0113	0.0228	CbGeAlD
Vidarabine—DPP4—hematopoietic system—sarcoma	0.011	0.0221	CbGeAlD
Vidarabine—DPP4—connective tissue—sarcoma	0.0106	0.0213	CbGeAlD
Vidarabine—ADK—smooth muscle tissue—sarcoma	0.00997	0.0201	CbGeAlD
Vidarabine—ADK—skin of body—sarcoma	0.00984	0.0199	CbGeAlD
Vidarabine—ADA—lymphoid tissue—sarcoma	0.00975	0.0197	CbGeAlD
Vidarabine—DPP4—smooth muscle tissue—sarcoma	0.00967	0.0195	CbGeAlD
Vidarabine—ADA—tendon—sarcoma	0.00917	0.0185	CbGeAlD
Vidarabine—ADA—bone marrow—sarcoma	0.00888	0.0179	CbGeAlD
Vidarabine—ADORA2A—lymphoid tissue—sarcoma	0.00887	0.0179	CbGeAlD
Vidarabine—ADK—cardiac atrium—sarcoma	0.0086	0.0173	CbGeAlD
Vidarabine—DPP4—uterus—sarcoma	0.00829	0.0167	CbGeAlD
Vidarabine—ADK—lymphoid tissue—sarcoma	0.00797	0.0161	CbGeAlD
Vidarabine—DPP4—lymphoid tissue—sarcoma	0.00773	0.0156	CbGeAlD
Vidarabine—ADA—testis—sarcoma	0.00759	0.0153	CbGeAlD
Vidarabine—ADK—tendon—sarcoma	0.00749	0.0151	CbGeAlD
Vidarabine—DPP4—tendon—sarcoma	0.00726	0.0146	CbGeAlD
Vidarabine—ADK—bone marrow—sarcoma	0.00726	0.0146	CbGeAlD
Vidarabine—DPP4—bone marrow—sarcoma	0.00704	0.0142	CbGeAlD
Vidarabine—ADORA2A—testis—sarcoma	0.00691	0.0139	CbGeAlD
Vidarabine—Adenosine monophosphate—SRC—sarcoma	0.00684	0.288	CrCbGaD
Vidarabine—ADORA2A—liver—sarcoma	0.00653	0.0132	CbGeAlD
Vidarabine—ADK—testis—sarcoma	0.0062	0.0125	CbGeAlD
Vidarabine—DPP4—testis—sarcoma	0.00601	0.0121	CbGeAlD
Vidarabine—ADK—liver—sarcoma	0.00587	0.0118	CbGeAlD
Vidarabine—DPP4—liver—sarcoma	0.00569	0.0115	CbGeAlD
Vidarabine—ADA—lymph node—sarcoma	0.0055	0.0111	CbGeAlD
Vidarabine—Apnoea—Etoposide—sarcoma	0.00459	0.00955	CcSEcCtD
Vidarabine—ADK—lymph node—sarcoma	0.0045	0.00907	CbGeAlD
Vidarabine—Sensory loss—Etoposide—sarcoma	0.00449	0.00935	CcSEcCtD
Vidarabine—Chest discomfort—Etoposide—sarcoma	0.0044	0.00915	CcSEcCtD
Vidarabine—DPP4—lymph node—sarcoma	0.00436	0.00879	CbGeAlD
Vidarabine—Cardiac failure—Thiotepa—sarcoma	0.00403	0.00838	CcSEcCtD
Vidarabine—Cardiac arrest—Thiotepa—sarcoma	0.00374	0.00778	CcSEcCtD
Vidarabine—Cardiac failure—Mitoxantrone—sarcoma	0.00348	0.00724	CcSEcCtD
Vidarabine—Cardiac arrest—Vincristine—sarcoma	0.00331	0.0069	CcSEcCtD
Vidarabine—Hyperventilation—Epirubicin—sarcoma	0.00317	0.0066	CcSEcCtD
Vidarabine—Burning sensation—Epirubicin—sarcoma	0.00314	0.00653	CcSEcCtD
Vidarabine—Ventricular arrhythmia—Epirubicin—sarcoma	0.00295	0.00613	CcSEcCtD
Vidarabine—Hyperventilation—Doxorubicin—sarcoma	0.00293	0.0061	CcSEcCtD
Vidarabine—Burning sensation—Doxorubicin—sarcoma	0.0029	0.00604	CcSEcCtD
Vidarabine—Cardiac failure—Etoposide—sarcoma	0.00289	0.00602	CcSEcCtD
Vidarabine—Scotoma—Epirubicin—sarcoma	0.00287	0.00598	CcSEcCtD
Vidarabine—Ventricular arrhythmia—Doxorubicin—sarcoma	0.00273	0.00567	CcSEcCtD
Vidarabine—Cardiac arrest—Etoposide—sarcoma	0.00268	0.00559	CcSEcCtD
Vidarabine—Scotoma—Doxorubicin—sarcoma	0.00266	0.00553	CcSEcCtD
Vidarabine—Acute coronary syndrome—Vincristine—sarcoma	0.00265	0.00551	CcSEcCtD
Vidarabine—Myocardial infarction—Vincristine—sarcoma	0.00263	0.00548	CcSEcCtD
Vidarabine—Drowsiness—Mitoxantrone—sarcoma	0.00262	0.00545	CcSEcCtD
Vidarabine—Acute coronary syndrome—Mitoxantrone—sarcoma	0.00258	0.00537	CcSEcCtD
Vidarabine—Sweating—Vincristine—sarcoma	0.00258	0.00536	CcSEcCtD
Vidarabine—Myocardial infarction—Mitoxantrone—sarcoma	0.00256	0.00534	CcSEcCtD
Vidarabine—Tinnitus—Thiotepa—sarcoma	0.00254	0.00528	CcSEcCtD
Vidarabine—Cardiac disorder—Thiotepa—sarcoma	0.00252	0.00525	CcSEcCtD
Vidarabine—Sweating—Mitoxantrone—sarcoma	0.00251	0.00522	CcSEcCtD
Vidarabine—Flushing—Dactinomycin—sarcoma	0.0025	0.00521	CcSEcCtD
Vidarabine—Mediastinal disorder—Thiotepa—sarcoma	0.00245	0.0051	CcSEcCtD
Vidarabine—Arrhythmia—Thiotepa—sarcoma	0.00243	0.00506	CcSEcCtD
Vidarabine—Ventricular extrasystoles—Epirubicin—sarcoma	0.00241	0.00503	CcSEcCtD
Vidarabine—Bronchospasm—Etoposide—sarcoma	0.0024	0.005	CcSEcCtD
Vidarabine—Hypoaesthesia—Vincristine—sarcoma	0.0024	0.00499	CcSEcCtD
Vidarabine—Bradycardia—Mitoxantrone—sarcoma	0.00239	0.00498	CcSEcCtD
Vidarabine—Tension—Thiotepa—sarcoma	0.00232	0.00484	CcSEcCtD
Vidarabine—Nervousness—Thiotepa—sarcoma	0.0023	0.00479	CcSEcCtD
Vidarabine—Back pain—Thiotepa—sarcoma	0.00229	0.00477	CcSEcCtD
Vidarabine—Atrioventricular block—Epirubicin—sarcoma	0.00225	0.00468	CcSEcCtD
Vidarabine—Cardiac disorder—Vincristine—sarcoma	0.00224	0.00466	CcSEcCtD
Vidarabine—Ventricular extrasystoles—Doxorubicin—sarcoma	0.00223	0.00465	CcSEcCtD
Vidarabine—Vision blurred—Thiotepa—sarcoma	0.00223	0.00464	CcSEcCtD
Vidarabine—Ventricular tachycardia—Epirubicin—sarcoma	0.00218	0.00454	CcSEcCtD
Vidarabine—Agitation—Thiotepa—sarcoma	0.00218	0.00453	CcSEcCtD
Vidarabine—Mediastinal disorder—Vincristine—sarcoma	0.00217	0.00452	CcSEcCtD
Vidarabine—Injection site reaction—Epirubicin—sarcoma	0.00217	0.00451	CcSEcCtD
Vidarabine—Acute coronary syndrome—Etoposide—sarcoma	0.00214	0.00447	CcSEcCtD
Vidarabine—Myocardial infarction—Etoposide—sarcoma	0.00213	0.00444	CcSEcCtD
Vidarabine—Arrhythmia—Mitoxantrone—sarcoma	0.0021	0.00437	CcSEcCtD
Vidarabine—Atrioventricular block—Doxorubicin—sarcoma	0.00208	0.00433	CcSEcCtD
Vidarabine—Cough—Thiotepa—sarcoma	0.00207	0.0043	CcSEcCtD
Vidarabine—Convulsion—Thiotepa—sarcoma	0.00205	0.00427	CcSEcCtD
Vidarabine—Hypertension—Thiotepa—sarcoma	0.00204	0.00425	CcSEcCtD
Vidarabine—Back pain—Vincristine—sarcoma	0.00203	0.00423	CcSEcCtD
Vidarabine—Ventricular tachycardia—Doxorubicin—sarcoma	0.00202	0.0042	CcSEcCtD
Vidarabine—Anxiety—Thiotepa—sarcoma	0.00201	0.00418	CcSEcCtD
Vidarabine—Injection site reaction—Doxorubicin—sarcoma	0.00201	0.00417	CcSEcCtD
Vidarabine—Dysgeusia—Mitoxantrone—sarcoma	0.002	0.00417	CcSEcCtD
Vidarabine—Back pain—Mitoxantrone—sarcoma	0.00198	0.00412	CcSEcCtD
Vidarabine—Discomfort—Dactinomycin—sarcoma	0.00198	0.00411	CcSEcCtD
Vidarabine—Hypoaesthesia—Etoposide—sarcoma	0.00194	0.00405	CcSEcCtD
Vidarabine—Agitation—Vincristine—sarcoma	0.00193	0.00402	CcSEcCtD
Vidarabine—Vision blurred—Mitoxantrone—sarcoma	0.00193	0.00401	CcSEcCtD
Vidarabine—Tachycardia—Thiotepa—sarcoma	0.00189	0.00393	CcSEcCtD
Vidarabine—Convulsion—Vincristine—sarcoma	0.00182	0.00379	CcSEcCtD
Vidarabine—Flushing—Etoposide—sarcoma	0.00181	0.00377	CcSEcCtD
Vidarabine—Cardiac disorder—Etoposide—sarcoma	0.00181	0.00377	CcSEcCtD
Vidarabine—Hypertension—Vincristine—sarcoma	0.00181	0.00377	CcSEcCtD
Vidarabine—Cough—Mitoxantrone—sarcoma	0.00178	0.00371	CcSEcCtD
Vidarabine—Convulsion—Mitoxantrone—sarcoma	0.00177	0.00369	CcSEcCtD
Vidarabine—Hypertension—Mitoxantrone—sarcoma	0.00176	0.00367	CcSEcCtD
Vidarabine—Mediastinal disorder—Etoposide—sarcoma	0.00176	0.00366	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Thiotepa—sarcoma	0.00176	0.00366	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.00175	0.00364	CcSEcCtD
Vidarabine—Chest pain—Mitoxantrone—sarcoma	0.00174	0.00362	CcSEcCtD
Vidarabine—Paraesthesia—Thiotepa—sarcoma	0.00173	0.00361	CcSEcCtD
Vidarabine—Anxiety—Mitoxantrone—sarcoma	0.00173	0.00361	CcSEcCtD
Vidarabine—Discomfort—Mitoxantrone—sarcoma	0.00172	0.00358	CcSEcCtD
Vidarabine—Somnolence—Thiotepa—sarcoma	0.00172	0.00358	CcSEcCtD
Vidarabine—Anaphylactic shock—Vincristine—sarcoma	0.00171	0.00357	CcSEcCtD
Vidarabine—Anaphylactic shock—Mitoxantrone—sarcoma	0.00167	0.00347	CcSEcCtD
Vidarabine—Dysgeusia—Etoposide—sarcoma	0.00167	0.00347	CcSEcCtD
Vidarabine—Hyperhidrosis—Vincristine—sarcoma	0.00166	0.00345	CcSEcCtD
Vidarabine—Pain—Thiotepa—sarcoma	0.00165	0.00344	CcSEcCtD
Vidarabine—Back pain—Etoposide—sarcoma	0.00164	0.00342	CcSEcCtD
Vidarabine—Shock—Mitoxantrone—sarcoma	0.00164	0.00342	CcSEcCtD
Vidarabine—Pain—Dactinomycin—sarcoma	0.00164	0.00341	CcSEcCtD
Vidarabine—Tachycardia—Mitoxantrone—sarcoma	0.00163	0.00339	CcSEcCtD
Vidarabine—Cardiac failure—Epirubicin—sarcoma	0.00162	0.00338	CcSEcCtD
Vidarabine—Cerebrovascular accident—Epirubicin—sarcoma	0.00162	0.00336	CcSEcCtD
Vidarabine—Hyperhidrosis—Mitoxantrone—sarcoma	0.00161	0.00336	CcSEcCtD
Vidarabine—Hypotension—Vincristine—sarcoma	0.0016	0.00333	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Vincristine—sarcoma	0.00156	0.00325	CcSEcCtD
Vidarabine—Hypotension—Mitoxantrone—sarcoma	0.00156	0.00325	CcSEcCtD
Vidarabine—Affect lability—Epirubicin—sarcoma	0.00156	0.00324	CcSEcCtD
Vidarabine—Paraesthesia—Vincristine—sarcoma	0.00154	0.0032	CcSEcCtD
Vidarabine—Urticaria—Thiotepa—sarcoma	0.00153	0.00319	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.00152	0.00316	CcSEcCtD
Vidarabine—Cardiac arrest—Epirubicin—sarcoma	0.0015	0.00313	CcSEcCtD
Vidarabine—Cardiac failure—Doxorubicin—sarcoma	0.0015	0.00312	CcSEcCtD
Vidarabine—Mood swings—Epirubicin—sarcoma	0.0015	0.00312	CcSEcCtD
Vidarabine—Paraesthesia—Mitoxantrone—sarcoma	0.0015	0.00312	CcSEcCtD
Vidarabine—Loss of consciousness—Etoposide—sarcoma	0.00149	0.00311	CcSEcCtD
Vidarabine—Cerebrovascular accident—Doxorubicin—sarcoma	0.00149	0.00311	CcSEcCtD
Vidarabine—Dyspnoea—Mitoxantrone—sarcoma	0.00149	0.0031	CcSEcCtD
Vidarabine—Cough—Etoposide—sarcoma	0.00148	0.00309	CcSEcCtD
Vidarabine—Somnolence—Mitoxantrone—sarcoma	0.00148	0.00309	CcSEcCtD
Vidarabine—Convulsion—Etoposide—sarcoma	0.00147	0.00307	CcSEcCtD
Vidarabine—Hypertension—Etoposide—sarcoma	0.00147	0.00306	CcSEcCtD
Vidarabine—Pain—Vincristine—sarcoma	0.00146	0.00305	CcSEcCtD
Vidarabine—Chest pain—Etoposide—sarcoma	0.00145	0.00301	CcSEcCtD
Vidarabine—Affect lability—Doxorubicin—sarcoma	0.00144	0.003	CcSEcCtD
Vidarabine—Discomfort—Etoposide—sarcoma	0.00143	0.00298	CcSEcCtD
Vidarabine—Pain—Mitoxantrone—sarcoma	0.00143	0.00297	CcSEcCtD
Vidarabine—Hypersensitivity—Thiotepa—sarcoma	0.00142	0.00296	CcSEcCtD
Vidarabine—Hypersensitivity—Dactinomycin—sarcoma	0.00141	0.00294	CcSEcCtD
Vidarabine—Cardiac arrest—Doxorubicin—sarcoma	0.00139	0.0029	CcSEcCtD
Vidarabine—Anaphylactic shock—Etoposide—sarcoma	0.00139	0.00289	CcSEcCtD
Vidarabine—Mood swings—Doxorubicin—sarcoma	0.00139	0.00289	CcSEcCtD
Vidarabine—Asthenia—Thiotepa—sarcoma	0.00139	0.00289	CcSEcCtD
Vidarabine—Asthenia—Dactinomycin—sarcoma	0.00138	0.00286	CcSEcCtD
Vidarabine—Tachycardia—Etoposide—sarcoma	0.00135	0.00282	CcSEcCtD
Vidarabine—Hyperhidrosis—Etoposide—sarcoma	0.00134	0.00279	CcSEcCtD
Vidarabine—Urticaria—Mitoxantrone—sarcoma	0.00133	0.00276	CcSEcCtD
Vidarabine—Hypotension—Etoposide—sarcoma	0.0013	0.0027	CcSEcCtD
Vidarabine—Dizziness—Thiotepa—sarcoma	0.00128	0.00266	CcSEcCtD
Vidarabine—Pollakiuria—Epirubicin—sarcoma	0.00126	0.00263	CcSEcCtD
Vidarabine—Hypersensitivity—Vincristine—sarcoma	0.00126	0.00263	CcSEcCtD
Vidarabine—Paraesthesia—Etoposide—sarcoma	0.00125	0.00259	CcSEcCtD
Vidarabine—Dyspnoea—Etoposide—sarcoma	0.00124	0.00258	CcSEcCtD
Vidarabine—Somnolence—Etoposide—sarcoma	0.00123	0.00257	CcSEcCtD
Vidarabine—Hypersensitivity—Mitoxantrone—sarcoma	0.00123	0.00256	CcSEcCtD
Vidarabine—Asthenia—Vincristine—sarcoma	0.00123	0.00256	CcSEcCtD
Vidarabine—Vomiting—Thiotepa—sarcoma	0.00123	0.00256	CcSEcCtD
Vidarabine—Drowsiness—Epirubicin—sarcoma	0.00122	0.00254	CcSEcCtD
Vidarabine—Vomiting—Dactinomycin—sarcoma	0.00122	0.00254	CcSEcCtD
Vidarabine—Rash—Thiotepa—sarcoma	0.00122	0.00254	CcSEcCtD
Vidarabine—Dermatitis—Thiotepa—sarcoma	0.00122	0.00253	CcSEcCtD
Vidarabine—Headache—Thiotepa—sarcoma	0.00121	0.00252	CcSEcCtD
Vidarabine—Rash—Dactinomycin—sarcoma	0.00121	0.00252	CcSEcCtD
Vidarabine—Asthenia—Mitoxantrone—sarcoma	0.0012	0.00249	CcSEcCtD
Vidarabine—Pain—Etoposide—sarcoma	0.00119	0.00247	CcSEcCtD
Vidarabine—Sweating—Epirubicin—sarcoma	0.00117	0.00243	CcSEcCtD
Vidarabine—Pollakiuria—Doxorubicin—sarcoma	0.00117	0.00243	CcSEcCtD
Vidarabine—Nausea—Thiotepa—sarcoma	0.00115	0.00239	CcSEcCtD
Vidarabine—Nausea—Dactinomycin—sarcoma	0.00114	0.00237	CcSEcCtD
Vidarabine—Dizziness—Vincristine—sarcoma	0.00113	0.00236	CcSEcCtD
Vidarabine—Drowsiness—Doxorubicin—sarcoma	0.00113	0.00235	CcSEcCtD
Vidarabine—Bradycardia—Epirubicin—sarcoma	0.00111	0.00232	CcSEcCtD
Vidarabine—Urticaria—Etoposide—sarcoma	0.0011	0.00229	CcSEcCtD
Vidarabine—Hypoaesthesia—Epirubicin—sarcoma	0.00109	0.00227	CcSEcCtD
Vidarabine—Vomiting—Vincristine—sarcoma	0.00109	0.00227	CcSEcCtD
Vidarabine—Sweating—Doxorubicin—sarcoma	0.00108	0.00225	CcSEcCtD
Vidarabine—Rash—Vincristine—sarcoma	0.00108	0.00225	CcSEcCtD
Vidarabine—Dermatitis—Vincristine—sarcoma	0.00108	0.00225	CcSEcCtD
Vidarabine—Headache—Vincristine—sarcoma	0.00107	0.00223	CcSEcCtD
Vidarabine—Vomiting—Mitoxantrone—sarcoma	0.00106	0.00221	CcSEcCtD
Vidarabine—Rash—Mitoxantrone—sarcoma	0.00105	0.00219	CcSEcCtD
Vidarabine—Dermatitis—Mitoxantrone—sarcoma	0.00105	0.00219	CcSEcCtD
Vidarabine—Headache—Mitoxantrone—sarcoma	0.00105	0.00218	CcSEcCtD
Vidarabine—Bradycardia—Doxorubicin—sarcoma	0.00103	0.00215	CcSEcCtD
Vidarabine—Hypersensitivity—Etoposide—sarcoma	0.00102	0.00213	CcSEcCtD
Vidarabine—Tinnitus—Epirubicin—sarcoma	0.00102	0.00213	CcSEcCtD
Vidarabine—Nausea—Vincristine—sarcoma	0.00102	0.00212	CcSEcCtD
Vidarabine—Flushing—Epirubicin—sarcoma	0.00102	0.00212	CcSEcCtD
Vidarabine—Cardiac disorder—Epirubicin—sarcoma	0.00102	0.00212	CcSEcCtD
Vidarabine—Hypoaesthesia—Doxorubicin—sarcoma	0.00101	0.0021	CcSEcCtD
Vidarabine—Asthenia—Etoposide—sarcoma	0.000996	0.00207	CcSEcCtD
Vidarabine—Nausea—Mitoxantrone—sarcoma	0.000991	0.00206	CcSEcCtD
Vidarabine—Mediastinal disorder—Epirubicin—sarcoma	0.000987	0.00205	CcSEcCtD
Vidarabine—Arrhythmia—Epirubicin—sarcoma	0.000978	0.00204	CcSEcCtD
Vidarabine—Tinnitus—Doxorubicin—sarcoma	0.000945	0.00197	CcSEcCtD
Vidarabine—Flushing—Doxorubicin—sarcoma	0.00094	0.00196	CcSEcCtD
Vidarabine—Cardiac disorder—Doxorubicin—sarcoma	0.00094	0.00196	CcSEcCtD
Vidarabine—Tension—Epirubicin—sarcoma	0.000935	0.00195	CcSEcCtD
Vidarabine—Dysgeusia—Epirubicin—sarcoma	0.000933	0.00194	CcSEcCtD
Vidarabine—Nervousness—Epirubicin—sarcoma	0.000926	0.00193	CcSEcCtD
Vidarabine—Back pain—Epirubicin—sarcoma	0.000922	0.00192	CcSEcCtD
Vidarabine—Dizziness—Etoposide—sarcoma	0.000918	0.00191	CcSEcCtD
Vidarabine—Mediastinal disorder—Doxorubicin—sarcoma	0.000913	0.0019	CcSEcCtD
Vidarabine—Arrhythmia—Doxorubicin—sarcoma	0.000905	0.00188	CcSEcCtD
Vidarabine—Vision blurred—Epirubicin—sarcoma	0.000898	0.00187	CcSEcCtD
Vidarabine—Vomiting—Etoposide—sarcoma	0.000882	0.00184	CcSEcCtD
Vidarabine—Agitation—Epirubicin—sarcoma	0.000876	0.00182	CcSEcCtD
Vidarabine—Rash—Etoposide—sarcoma	0.000875	0.00182	CcSEcCtD
Vidarabine—Dermatitis—Etoposide—sarcoma	0.000874	0.00182	CcSEcCtD
Vidarabine—Headache—Etoposide—sarcoma	0.000869	0.00181	CcSEcCtD
Vidarabine—Tension—Doxorubicin—sarcoma	0.000865	0.0018	CcSEcCtD
Vidarabine—Dysgeusia—Doxorubicin—sarcoma	0.000864	0.0018	CcSEcCtD
Vidarabine—Nervousness—Doxorubicin—sarcoma	0.000857	0.00178	CcSEcCtD
Vidarabine—Syncope—Epirubicin—sarcoma	0.000855	0.00178	CcSEcCtD
Vidarabine—Back pain—Doxorubicin—sarcoma	0.000853	0.00178	CcSEcCtD
Vidarabine—Palpitations—Epirubicin—sarcoma	0.000842	0.00175	CcSEcCtD
Vidarabine—Loss of consciousness—Epirubicin—sarcoma	0.000838	0.00174	CcSEcCtD
Vidarabine—Cough—Epirubicin—sarcoma	0.000832	0.00173	CcSEcCtD
Vidarabine—Vision blurred—Doxorubicin—sarcoma	0.000831	0.00173	CcSEcCtD
Vidarabine—Convulsion—Epirubicin—sarcoma	0.000826	0.00172	CcSEcCtD
Vidarabine—Nausea—Etoposide—sarcoma	0.000824	0.00172	CcSEcCtD
Vidarabine—Hypertension—Epirubicin—sarcoma	0.000823	0.00171	CcSEcCtD
Vidarabine—Chest pain—Epirubicin—sarcoma	0.000811	0.00169	CcSEcCtD
Vidarabine—Agitation—Doxorubicin—sarcoma	0.00081	0.00169	CcSEcCtD
Vidarabine—Anxiety—Epirubicin—sarcoma	0.000809	0.00168	CcSEcCtD
Vidarabine—Discomfort—Epirubicin—sarcoma	0.000802	0.00167	CcSEcCtD
Vidarabine—Dry mouth—Epirubicin—sarcoma	0.000794	0.00165	CcSEcCtD
Vidarabine—Syncope—Doxorubicin—sarcoma	0.000791	0.00165	CcSEcCtD
Vidarabine—Palpitations—Doxorubicin—sarcoma	0.000779	0.00162	CcSEcCtD
Vidarabine—Anaphylactic shock—Epirubicin—sarcoma	0.000778	0.00162	CcSEcCtD
Vidarabine—Loss of consciousness—Doxorubicin—sarcoma	0.000775	0.00161	CcSEcCtD
Vidarabine—Cough—Doxorubicin—sarcoma	0.00077	0.0016	CcSEcCtD
Vidarabine—Shock—Epirubicin—sarcoma	0.000765	0.00159	CcSEcCtD
Vidarabine—Convulsion—Doxorubicin—sarcoma	0.000764	0.00159	CcSEcCtD
Vidarabine—Hypertension—Doxorubicin—sarcoma	0.000761	0.00159	CcSEcCtD
Vidarabine—Tachycardia—Epirubicin—sarcoma	0.000759	0.00158	CcSEcCtD
Vidarabine—Hyperhidrosis—Epirubicin—sarcoma	0.000752	0.00157	CcSEcCtD
Vidarabine—Chest pain—Doxorubicin—sarcoma	0.000751	0.00156	CcSEcCtD
Vidarabine—Anxiety—Doxorubicin—sarcoma	0.000748	0.00156	CcSEcCtD
Vidarabine—Discomfort—Doxorubicin—sarcoma	0.000742	0.00154	CcSEcCtD
Vidarabine—Dry mouth—Doxorubicin—sarcoma	0.000734	0.00153	CcSEcCtD
Vidarabine—Hypotension—Epirubicin—sarcoma	0.000727	0.00151	CcSEcCtD
Vidarabine—Anaphylactic shock—Doxorubicin—sarcoma	0.00072	0.0015	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000709	0.00148	CcSEcCtD
Vidarabine—Shock—Doxorubicin—sarcoma	0.000708	0.00147	CcSEcCtD
Vidarabine—Tachycardia—Doxorubicin—sarcoma	0.000702	0.00146	CcSEcCtD
Vidarabine—Paraesthesia—Epirubicin—sarcoma	0.000699	0.00145	CcSEcCtD
Vidarabine—Hyperhidrosis—Doxorubicin—sarcoma	0.000696	0.00145	CcSEcCtD
Vidarabine—Dyspnoea—Epirubicin—sarcoma	0.000694	0.00144	CcSEcCtD
Vidarabine—Somnolence—Epirubicin—sarcoma	0.000692	0.00144	CcSEcCtD
Vidarabine—Hypotension—Doxorubicin—sarcoma	0.000673	0.0014	CcSEcCtD
Vidarabine—Pain—Epirubicin—sarcoma	0.000665	0.00138	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000656	0.00137	CcSEcCtD
Vidarabine—Paraesthesia—Doxorubicin—sarcoma	0.000646	0.00135	CcSEcCtD
Vidarabine—Dyspnoea—Doxorubicin—sarcoma	0.000642	0.00134	CcSEcCtD
Vidarabine—Somnolence—Doxorubicin—sarcoma	0.00064	0.00133	CcSEcCtD
Vidarabine—Urticaria—Epirubicin—sarcoma	0.000618	0.00129	CcSEcCtD
Vidarabine—Pain—Doxorubicin—sarcoma	0.000616	0.00128	CcSEcCtD
Vidarabine—Hypersensitivity—Epirubicin—sarcoma	0.000573	0.00119	CcSEcCtD
Vidarabine—Urticaria—Doxorubicin—sarcoma	0.000572	0.00119	CcSEcCtD
Vidarabine—Asthenia—Epirubicin—sarcoma	0.000558	0.00116	CcSEcCtD
Vidarabine—Hypersensitivity—Doxorubicin—sarcoma	0.00053	0.0011	CcSEcCtD
Vidarabine—Asthenia—Doxorubicin—sarcoma	0.000516	0.00108	CcSEcCtD
Vidarabine—Dizziness—Epirubicin—sarcoma	0.000514	0.00107	CcSEcCtD
Vidarabine—Vomiting—Epirubicin—sarcoma	0.000495	0.00103	CcSEcCtD
Vidarabine—Rash—Epirubicin—sarcoma	0.00049	0.00102	CcSEcCtD
Vidarabine—Dermatitis—Epirubicin—sarcoma	0.00049	0.00102	CcSEcCtD
Vidarabine—Headache—Epirubicin—sarcoma	0.000487	0.00101	CcSEcCtD
Vidarabine—Dizziness—Doxorubicin—sarcoma	0.000476	0.000991	CcSEcCtD
Vidarabine—Nausea—Epirubicin—sarcoma	0.000462	0.000962	CcSEcCtD
Vidarabine—Vomiting—Doxorubicin—sarcoma	0.000458	0.000953	CcSEcCtD
Vidarabine—Rash—Doxorubicin—sarcoma	0.000454	0.000945	CcSEcCtD
Vidarabine—Dermatitis—Doxorubicin—sarcoma	0.000453	0.000944	CcSEcCtD
Vidarabine—Headache—Doxorubicin—sarcoma	0.000451	0.000939	CcSEcCtD
Vidarabine—Nausea—Doxorubicin—sarcoma	0.000428	0.00089	CcSEcCtD
